Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 3/2009

01-09-2009 | Original Research Article

Use of, Satisfaction with, and Willingness to Switch Prescription and Over-The-Counter Treatments for Chronic Urticaria

An Online Survey

Authors: Dr Donald E. Stull, Sonia Gavriel

Published in: The Patient - Patient-Centered Outcomes Research | Issue 3/2009

Login to get access

Abstract

Background: Chronic urticaria (hives) affects a sizeable number of people worldwide, perhaps as much as 3%. It is often accompanied by angioedema. The negative effects of urticaria and angioedema, and any adverse effects of treatment, can result in significant patient burden.
Objective: To explore patients’ use of, preferences for, and willingness to switch from prescription to over-the-counter (OTC) treatments for chronic urticaria. In addition, we compared treatment satisfaction with the treatment used most recently for their chronic urticaria.
Methods: Data were collected by an online survey using members of international consumer survey panels representative of the general populations in France and Germany. Panelists with urticaria were selected based on answers to screening questions. Respondents were asked, in their native language, questions about their typical course of treatment (prescription vs OTC), satisfaction with treatment, troublesomeness of their typical outbreak, whether their condition had improved or become worse over the past 12 months, and their willingness to try a new treatment if one became available. Descriptive analyses were performed on selected variables. Groups were compared using difference of means tests. Correlations and multiple regressions were performed to assess predictors of satisfaction with treatment and likelihood of switching treatment.
Results: The final study sample consisted of 405 patients. Patients who used prescription treatments were more satisfied and reported greater treatment benefits with their treatment than those using OTC treatments. Patients who felt that their condition had become worse over the past 12 months were more likely to consider switching treatments. Respondents who used Aerius® (desloratadine) most recently for treating their symptoms reported greater satisfaction with treatment than did those who used other commonly used prescription treatments most recently.
Conclusions: These results suggest that prescription treatments for chronic urticaria have a valuable place amongst the treatments offered for this very uncomfortable condition. Moreover, patients expressed preference for prescription treatments in large part because they felt that these treatments work.
Literature
1.
go back to reference McGirt LY, Vasagar K, Gober LM, et al. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006 Oct; 142(10): 1337–42PubMedCrossRef McGirt LY, Vasagar K, Gober LM, et al. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006 Oct; 142(10): 1337–42PubMedCrossRef
2.
go back to reference Katelaris CH, Peake JE. Allergy and the skin: eczema and chronic urticaria. Med J Aust 2006; 185(9): 517–22PubMed Katelaris CH, Peake JE. Allergy and the skin: eczema and chronic urticaria. Med J Aust 2006; 185(9): 517–22PubMed
4.
go back to reference Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006 Mar–Apr; 27(2): 96–9PubMed Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006 Mar–Apr; 27(2): 96–9PubMed
5.
go back to reference Goetz D, Jacobson JM, Murnane JE, et al. Prolongation of simple and choice reaction times in a double-blind comparison of twice-daily hydroxyzine versus terfenadine. J Allergy Clin Immunol 1989; 84: 316–22PubMedCrossRef Goetz D, Jacobson JM, Murnane JE, et al. Prolongation of simple and choice reaction times in a double-blind comparison of twice-daily hydroxyzine versus terfenadine. J Allergy Clin Immunol 1989; 84: 316–22PubMedCrossRef
6.
go back to reference Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy 1993; 71: 121–6PubMed Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy 1993; 71: 121–6PubMed
7.
go back to reference Weiler JM, Bloomfield JR, Woodworth GG. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo controlled trial in the Iowa driving stimulator. Ann Intern Med 2000; 132: 354–63PubMed Weiler JM, Bloomfield JR, Woodworth GG. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo controlled trial in the Iowa driving stimulator. Ann Intern Med 2000; 132: 354–63PubMed
9.
go back to reference Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004; 114: 619–25PubMedCrossRef Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004; 114: 619–25PubMedCrossRef
10.
go back to reference Moldofsky H, Scarisbrick P, England R, et al. Musculo-skeletal symptoms and non-REM sleep disturbances in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975; 37: 341–51PubMed Moldofsky H, Scarisbrick P, England R, et al. Musculo-skeletal symptoms and non-REM sleep disturbances in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975; 37: 341–51PubMed
11.
go back to reference Roth T, Roerhs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone 2003; 5: 5–15PubMedCrossRef Roth T, Roerhs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone 2003; 5: 5–15PubMedCrossRef
12.
go back to reference Raap U, Geiler U, Schmid-Ott G. Urticaria. Dermatol Psychosom 2004; 5: 203–5CrossRef Raap U, Geiler U, Schmid-Ott G. Urticaria. Dermatol Psychosom 2004; 5: 203–5CrossRef
13.
go back to reference Kaplan AP. Chronic urticaria: new concepts regarding pathogenesis and treatment. Curr Allergy Asthma Rep 2002; 2: 263–4PubMedCrossRef Kaplan AP. Chronic urticaria: new concepts regarding pathogenesis and treatment. Curr Allergy Asthma Rep 2002; 2: 263–4PubMedCrossRef
14.
go back to reference Stanaland BE. Treatment of patients with chronic idiopathic urticaria. Clin Rev Allergy Immunol 2002; 23: 233–41PubMedCrossRef Stanaland BE. Treatment of patients with chronic idiopathic urticaria. Clin Rev Allergy Immunol 2002; 23: 233–41PubMedCrossRef
15.
go back to reference Sanada S, Tanaka T, Kameyoshi Y, et al. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res 2005; 297: 134–8PubMedCrossRef Sanada S, Tanaka T, Kameyoshi Y, et al. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res 2005; 297: 134–8PubMedCrossRef
16.
go back to reference Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114: 465–75PubMedCrossRef Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114: 465–75PubMedCrossRef
17.
go back to reference Espin J, Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Brussels: European Commission, 2007 Espin J, Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. Brussels: European Commission, 2007
18.
go back to reference Habel C, Antony K, Arts D, et al., for the Austrian Health Institute (Österreichisches Bundesinstitut für Gesundheitswesen, ÖBIG). Surveying, assessing and analysing the pharmaceutical sector in the 25 EU member states. Vienna: European Communities, 2006 Habel C, Antony K, Arts D, et al., for the Austrian Health Institute (Österreichisches Bundesinstitut für Gesundheitswesen, ÖBIG). Surveying, assessing and analysing the pharmaceutical sector in the 25 EU member states. Vienna: European Communities, 2006
19.
go back to reference Toubi E, Kessel A, Avshovich N. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004; 59: 869–73PubMedCrossRef Toubi E, Kessel A, Avshovich N. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004; 59: 869–73PubMedCrossRef
Metadata
Title
Use of, Satisfaction with, and Willingness to Switch Prescription and Over-The-Counter Treatments for Chronic Urticaria
An Online Survey
Authors
Dr Donald E. Stull
Sonia Gavriel
Publication date
01-09-2009
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 3/2009
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.2165/11314870-000000000-00000

Other articles of this Issue 3/2009

The Patient - Patient-Centered Outcomes Research 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine